We studied whether a novel vasoconstrictor peptide, endothelin-1 (ET-1), is synthesized by and released from human carcinoma cell lines, and whether ET-1 stimulates proliferation of these tumor cells. ET-1-like immunoreactivity was released from both HeLa and HEp-2 cells as a function of time. Reverse-phase HPLC of the conditioned media from HeLa cells revealed a major peak coeluting with standard ET-1. Northern blot analysis demonstrated the expression of mRNA for ET-1 precursor in both tumor cell lines. Both cell lines contained a single class of specific binding sites for ET-1. ET-1 dose-dependently induced increases in cytosolic free Ca2+ concentration in fura-2-loaded tumor cells, whose effect was completely abolished by chelating extracellular Ca2+ or by Ca(2+)-channel blocker. ET-1 stimulated proliferation of the quiescent cell lines in a dose-dependent manner, whose effect was inhibited by Ca(2+)-channel blocker. Polyclonal antibody for ET-1 inhibited proliferation of these cell lines, whereas nonimmune serum had no effect. These results demonstrate that ET-1 is synthesized by and released from human epithelial carcinoma cell lines, and that exogenous and endogenous ET-1 stimulates proliferation of the cells possibly through Ca2+ influx, suggesting its role as an autocrine/paracrine growth factor for certain tumor cells. 
Introduction
Endothelin-l (ET-1),' originally characterized from the supernatant of cultured porcine endothelial cells, is a potent vasoconstrictor/pressor peptide (1) . Subsequent cDNAdcloning of human genomic library revealed three isopeptides, termed ET-1, ET-2, and ET-3 (1, 2) . Specific receptors for ET-1 are distributed not only in cardiovascular system, but also in a wide variety of tissues (3), suggesting its diverse physiological functions. Recently, it has been reported that ET-1 stimulates proliferation ofrat vascular smooth muscle cells (4) , fibroblasts (5) , and glomerular mesangial cells (6) , and the expression of protooncogenes (c-myc, c-fos) in these cells, suggesting its potential role as a growth factor. At present, no information is yet available whether ET-1 is produced by carcinoma cells and acts by themselves. In the present study, we demonstrate that two epithelial carcinoma cell lines derived from human cervix (HeLa) and larynx (HEp-2) express mRNA for ET-1 precursor, and release ET-1 into medium, and further show that both tumor cells possess specific ET-1 receptors through which ET-1 stimulates cell proliferation possibly via influx of extracellular Ca2+.
Methods
Cell culture. HeLa cells (American Type Culture Collection, Rockville, MD) were cultured in MEM supplemented with 2 mM glutamine and 10% fetal bovine serum (FBS), and HEp-2 cells (ATCC) in Eagle's MEM with Earle's balanced salt solution and 10% FBS at 370C in a 95% room air-5% CO2 humidified incubator. Medium was changed every 2-3 d. After reaching confluency, cells were replaced with a serum-free MEM for 2 d. The conditioned media were pooled and stored at -40'C until processed for extraction. Cell number was measured by Coulter Counter Model ZM (Coulter Electronics, Inc., Hialeah, FL).
Extraction ofET-1. For chromatographic analysis, the pooled conditioned media (100 ml) were acidified with 0.1% trifluoroacetic acid (TFA), and the supernatant applied to Spe C8 cartridge (J. T. Baker Chemical Co., Phillipsburg, NJ) and eluted with 2 ml 60% acetonitrile/ 0.1% TFA, as reported previously (7) . The eluates were evaporated to dryness and subjected to reverse-phase HPLC. The recovery of synthetic ET-l during the extraction procedure was 77%.
Radioimmunoassay (RIA). ET-1-like immunoreactivity (LI) was determined by specific RIA for ET-I as reported (7) . The antibody used in the present RIA mainly recognizes the COOH-terminal Trp2' residue of ET-1, and cross-reacts fully with ET-2 and ET-3, but not with big ET-1, or other polypeptide hormones. The final dilution of antiserum was 1:150,000. The bound ligands were separated from the free ones by the double antibody method. The sensitivity of ET-I RIA was 1.0 fmol/tube, and the 50% intercept was 14 fmol/tube. The intra-and interassay variations were 3.2 and 8.6%, respectively.
Reverse-phase HPLC. SDS at 60'C, and autoradiographed on a Kodak XAR-l film with an intensifying screen at -80'C for 8-16 h (8) .
Binding experiments. Binding experiments were performed essentially in the same manner as previously described (9) were dispersed with 0.25% trypsin and 0.02% EDTA, and incubated with 5 ,iM fura-2 acetoxymethylester (Dojin Chemical, Kumamoto, Japan) at 37°C for 20 min in HBSS. Suspended fura-2-loaded cells were washed, and incubated for 20 min in physiological salt solution (130 mM NaCl, 5 mM KC1, 1 mM MgCl2, 1.5 mM CaCl2, and 20 mM Hepes, pH 7.4), containing 0.5% BSA and 10 mM glucose to allow for intracellular dye cleavage. Fluorescence of fura-2-loaded suspended cells (5 X 106 cells/ml) was measured at 37°C using continuous rapid alternating excitation from dual monochromators (340 and 380 nm), and emission at 505 nm (CAF-100, Japan Spectroscopic Co. Ltd., To- kyo) as reported (9) . Fluorescent measurement was converted to [Ca2+] by determining the maximal fluorescence (Rmax) with 10% Triton X-100, followed by the minimal fluorescence (Rmin) with 15 Cell proliferation. Cells were seeded into 12-well cluster dishes (2.9 x 104 cells/well). After 24 h, the cells were washed, and replaced with 2 ml serum-free MEM with or without ET-I and incubated for the indicated times. After completion, cells were trypsinized, and the cell number was measured by Coulter Counter. To determine whether the antibody for ET-l used for RIA affects the cell proliferation, tumor cells which had been replaced with fresh MEM containing 0.2% FBS (HeLa cells) or 3% FBS (HEp-2 cells) were incubated in the absence and presence of various dilutions (1:1,000-1:1,000,000) of rabbit ET-l antiserum and nonimmune rabbit serum ( Northern blot analysis of poly(A)+ RNA from both tumor cells using cDNA from human prepro-ET-1 as a probe is shown in Fig. 3 . A single hybridization band corresponding to the size (2.3 kb) of mRNA coding for human prepro-ET-1 was demonstrated in both cells.
To characterize the specific binding sites for ET-I in these tumor cells, binding study using 1251-ET-l as a radioligand was performed. Unlabeled ET-I competitively inhibited the bind- Under serum-free conditions, ET-1 significantly (P < 0.01) stimulated proliferation of HeLa cells in a dose-dependent manner (10-3-_10-9 M) and that of HEp-2 cells to the less extent (I0-8 10-7 M) after 72 h (Fig. 6) . In HeLa cells, ET-l as low as 10-13 M induced an approximate twofold increase in cell number and maximal stimulation (approximate fourfold increase) was observed at 10-9 M; the approximate EDse was 3 X 10-12 M. The ET-l-induced proliferation of HeLa cells was attenuated by 1O-8 M nicardipine and completely inhibited by 10-7 M nicardipine, whereas nicardipine (I0-l-0I' M) added alone did not affect cell growth (data not shown). Addition of rabbit anti-ET-serum dose-dependently inhibited proliferation of HeLa cells [95.2±1.2% (1:1,000,000); 86.0±4.8% (1:100,000); 75.2±6.0% (1:10,000); 37.6±2.9% (1:1,000)], whereas the antiserum only at a high concentration (1: 1,000) significantly inhibited proliferation of HEp-2 cells (Fig. 6) . Nonimmune rabbit serum (1: 1,000) had no effect on prolifera- Synthetic ET-1 dose-dependently stimulated the proliferation of quiescent tumor cells, of which effect was also far more effective in HeLa cells than in HEp-2. These data indicate that ET-1 is a potent mitogen not only for normal cells, but for tumor cells as well. It should be noted that the minimum effective concentration to induce mitogenic effect on HeLa cells by ET-l (-l0 o1 M) is comparable with that of circulating ET-I in humans (-6 X I0-`M) (7) and far lower than those (-10-`M) to induce mitogenesis in other cells, such as rat vascular smooth muscle cells (4), fibroblasts (5) , and glomerular mesangial cells (6) . Furthermore, the potency of ET-1 for proliferation ofthe cells closely corresponded to that for [Ca2+]i increase and the ET-1-stimulated growth of these cells was inhibitable with voltage-dependent Ca2+-channel blocker. These data are compatible with the importance of Ca2+ influx for the ET-1-induced mitogenesis in rat vascular smooth muscle cells (4) . Taken together, we speculate that Ca2+ influx through DHP-sensitive Ca2+ channels may be involved in the mechanism of the ET-1-induced proliferation of tumor cells.
The neutralization experiments using ET-1 antibody revealed that the proliferation of HeLa cells was inhibited more effectively than that ofHEp-2 cells by coincubation with rabbit anti-ET-1 antiserum, but not with nonimmune rabbit serum. These data are consistent with the differential effects by exogenous ET-1 on [Ca2+]i increases and growth ofthese tumor cells. HEp-2 cells compared with those of HeLa cells in the present study might argue against the major role of ET-1 as an autocrine factor for HEp-2 cells, but for its paracrine role for the neighboring stromal cells as suggested (16) . Therefore, it remains unsettled whether ET-1 production by the tumor cell lines in general acts either as an autocrine growth factor for their own cells or as a paracrine growth factor for other cells.
In conclusion, the present study demonstrates that ET-1 is synthesized by and released from human carcinoma cell lines, and that ET-l stimulates proliferation of these cells through receptor-mediated increase in [Ca2"Ji, possibly derived from Ca2" influx. Our data thus suggest that ET-1 produced by the tumor cells may function as an autocrine/paracrine growth factor for certain tumor cells.
